NORRIS.BO · BSE
NORRIS MEDICINES LTD.
₹18.24
+3.64% (+₹0.64)
Prev. close
₹17.6
Volume
5,340
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About NORRIS MEDICINES LTD.
Norris Medicines Limited manufactures and sells pharmaceutical formulations in India. The company offers nonsterile dosage products, such as tablets, capsules, liquid orals, and copical ointments, as well as injections and medicinal formulations. Its products include antibiotics, anti-inflammatory/pain management, antiemetic, nutrition, gastro, cough/cold, skin and allergy, antimalarial, diabetic, cardiac, dental, and other medicine products. The company also provides contract and loan license manufacturing services for pharma companies. It exports its products. Norris Medicines Limited was incorporated in 1990 and is based in Ankleshwar, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Vimal Dhirendra Shah
Headquarters
Ankleshwar
Employees
18
Website
norrispharma.comExchange
View on BSE ↗Key stats
Market cap
₹18.24 Cr
Beta (1Y · daily vs NIFTY 50)
0.32
Beta (5Y · monthly vs NIFTY 50)
0.51
Shares float
23.82 L
EPS · quarter ended Mar 2025
₹-0.23
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2026 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2026. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹12.25 Cr | ₹9.44 Cr | ₹8.36 Cr | ₹5.64 Cr | ₹5.82 Cr | ₹8.13 Cr | |
| EBITDA | ₹-1.69 Cr | ₹-4.66 L | ₹93.71 L | ₹-15.66 L | ₹-20.14 L | ₹70.98 L |
| ₹-4.96 Cr | ₹-3.26 Cr | ₹-1.75 Cr | ₹-1.19 Cr | ₹-1.24 Cr | ₹-28.10 L | |
| Diluted EPS | ₹-4.96 | ₹-3.26 | ₹-1.75 | ₹-1.19 | ₹-1.24 | ₹-0.28 |
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| NORRIS MEDICINES LTD. | ₹15.22 Cr | ₹15.22 | — | — | — | — | — | -9.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 14
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.